An Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Determination of 4 β-Lactam Antibiotics, Tazobactam, and Linezolid in Human Plasma Samples.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
received:
11
04
2022
accepted:
25
06
2022
pubmed:
17
8
2022
medline:
16
11
2022
entrez:
16
8
2022
Statut:
ppublish
Résumé
Optimization of antimicrobial therapy is a challenge in critically ill patients who develop extreme interindividual and intraindividual pharmacokinetic variability. Therapeutic drug monitoring is a valuable tool for maximizing the effect of a drug and minimizing its adverse and unwanted effects. The aim of the current work was to develop and validate an ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method to determine multiple antibiotics in clinical plasma samples from critically ill patients; low sample volume and rapid processing of samples were considered the main criteria. A separation method based on an online combination of UHPLC-MS/MS was developed for the simultaneous determination of 4 β-lactam antibiotics (cefepime, meropenem, cefotaxime, and piperacillin), tazobactam, and linezolid in human plasma samples. The volume of plasma sample used for analysis was 20 µL. The developed method was validated according to Food and Drug Administration guidelines. The chromatographic run time was 8 minutes. Calibration curves were linear for concentration ranges of 0.1-100 mcg/mL (r 2 > 0.99) for tazobactam, meropenem, cefotaxime, linezolid, and piperacillin and 1-100 mcg/mL (r 2 > 0.99) for cefepime. The intraday and interday accuracy of the method ranged from 92.4% to 110.7% and 93.6% to 113.3%, respectively. The intraday and interday precision values were ≤17.3% and ≤17.4%, respectively. No interfering and carryover analytes were observed. The developed UHPLC-MS/MS method is an appropriate and practical tool for therapeutic drug monitoring of the selected antibiotics. Owing to its rapidity, requirement of low sample volume, and high selectivity, sensitivity, and reliability, it can be effectively implemented in routine clinical laboratory tests for critically ill patients.
Sections du résumé
BACKGROUND
Optimization of antimicrobial therapy is a challenge in critically ill patients who develop extreme interindividual and intraindividual pharmacokinetic variability. Therapeutic drug monitoring is a valuable tool for maximizing the effect of a drug and minimizing its adverse and unwanted effects. The aim of the current work was to develop and validate an ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method to determine multiple antibiotics in clinical plasma samples from critically ill patients; low sample volume and rapid processing of samples were considered the main criteria.
METHODS
A separation method based on an online combination of UHPLC-MS/MS was developed for the simultaneous determination of 4 β-lactam antibiotics (cefepime, meropenem, cefotaxime, and piperacillin), tazobactam, and linezolid in human plasma samples. The volume of plasma sample used for analysis was 20 µL. The developed method was validated according to Food and Drug Administration guidelines.
RESULTS
The chromatographic run time was 8 minutes. Calibration curves were linear for concentration ranges of 0.1-100 mcg/mL (r 2 > 0.99) for tazobactam, meropenem, cefotaxime, linezolid, and piperacillin and 1-100 mcg/mL (r 2 > 0.99) for cefepime. The intraday and interday accuracy of the method ranged from 92.4% to 110.7% and 93.6% to 113.3%, respectively. The intraday and interday precision values were ≤17.3% and ≤17.4%, respectively. No interfering and carryover analytes were observed.
CONCLUSIONS
The developed UHPLC-MS/MS method is an appropriate and practical tool for therapeutic drug monitoring of the selected antibiotics. Owing to its rapidity, requirement of low sample volume, and high selectivity, sensitivity, and reliability, it can be effectively implemented in routine clinical laboratory tests for critically ill patients.
Identifiants
pubmed: 35971670
doi: 10.1097/FTD.0000000000001017
pii: 00007691-202212000-00010
doi:
Substances chimiques
Tazobactam
SE10G96M8W
Linezolid
ISQ9I6J12J
Meropenem
FV9J3JU8B1
Cefepime
807PW4VQE3
Piperacillin
X00B0D5O0E
Anti-Bacterial Agents
0
Monobactams
0
Cefotaxime
N2GI8B1GK7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
784-790Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Bush K, Bradford PA. β-lactams and β-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6:a025247.
Fratoni AJ, Nicolau DP, Kuti JL, et al. A guide to therapeutic drug monitoring of β-lactam antibiotics. Pharmacotherapy . 2021;41:220–233.
Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46:1127–1153.
Roberts JA, Ulldemolins M, Roberts MS, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents . 2010;36:332–339.
Tuzimski T, Petruczynik A. Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM). Molecules . 2020;25:4026.
Verhoven SM, Groszek JJ, Fissell WH, et al. Therapeutic drug monitoring of piperacillin and tazobactam by RP-HPLC of residual blood specimens. Clin Chim Acta. 2018;482:60–64.
Pinder N, Brenner T, Swoboda S, et al. Therapeutic drug monitoring of beta-lactam antibiotics–influence of sample stability on the analysis of piperacillin, meropenem, ceftazidime and flucloxacillin by HPLC-UV. J Pharm Biomed Anal. 2017;143:86–93.
Bricheux A, Lenggenhager L, Hughes S, et al. Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: a retrospective cohort study. Clin Microbiol Infect. 2019;25:383.e1–383.e4.
Legrand T, Vodovar D, Tournier N, et al. Simultaneous determination of eight β-lactam antibiotics, amoxicillin, cefazolin, cefepime, cefotaxime, ceftazidime, cloxacillin, oxacillin, and piperacillin, in human plasma by using ultra-high-performance liquid chromatography with ultraviolet detection. Antimicrob Agents Chemother. 2016;60:4734–4742.
Verdier MC, Tribut O, Tattevin P, et al. Determination of 12 beta-lactam antibiotics in human plasma by high-performance liquid chromatography with UV detection: application to therapeutic drug monitoring. Antimicrob Agents Chemother. 2011;55:4873–4879.
Lopez KJ, Bertoluci DF, Vicente KM, et al. Simultaneous determination of cefepime, vancomycin and imipenem in human plasma of burn patients by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci . 2007;860:241–245.
Denooz R, Charlier C. Simultaneous determination of five beta-lactam antibiotics (cefepim, ceftazidime, cefuroxime, meropenem and piperacillin) in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;864:161–167.
McWhinney BC, Wallis SC, Hillister T, et al. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2039–2043.
D'Cunha R, Bach T, Young BA, et al. Quantification of cefepime, meropenem, piperacillin, and tazobactam in human plasma using a sensitive and robust liquid chromatography-tandem mass spectrometry method, part 1: assay development and validation. Antimicrob Agents Chemother. 2018;62:e00859–18.
El-Najjar N, Jantsch J, Gessner A, et al. The use of liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of antibiotics in cancer patients. Clin Chem Lab Med. 2017;55:1246–1261.
Shipkova M, Svinarov D. LC-MS/MS as a tool for TDM services: where are we? Clin Biochem. 2016;49:1009–1023.
Chen F, Hu Z-Y, Laizure SC, et al. Simultaneous assay of multiple antibiotics in human plasma by LC-MS/MS: importance of optimizing formic acid concentration. Bioanalysis . 2017;9:469–483.
Rigo-Bonnin R, Ribera A, Arbiol-Roca S, et al. Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of β-lactam antibiotic concentration in human plasma. Clin Chim Acta . 2017;468:215–224.
D'Cunha R, Bach T, Young BA, et al. Quantification of cefepime, meropenem, piperacillin, and tazobactam in human plasma using a sensitive and robust liquid chromatography-tandem mass spectrometry method, part 2: stability evaluation. Antimicrob Agents Chemother. 2018;62:e00861–18.
Zhang M, Moore GA, Chin PKL, et al. Simultaneous determination of cephalexin, cefazolin, flucloxacillin, and probenecid by liquid chromatography-tandem mass spectrometry for total and unbound concentrations in human plasma. Ther Drug Monit. 2018;40:682–692.
Neugebauer S, Wichmann C, Bremer-Streck S, et al. Simultaneous quantification of nine antimicrobials by LC-MS/MS for therapeutic drug monitoring in critically ill patients. Ther Drug Monit. 2019;41:29–37.
Ferrari D, Ripa M, Premaschi S, et al. LC-MS/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples. J Pharm Biomed Anal. 2019;169:11–18.
Rehm S, Rentsch KM. HILIC LC-MS/MS method for the quantification of cefepime, imipenem and meropenem. J Pharm Biomed Anal. 2020;186:113289.
Rakete S, Schuster C, Paal M, et al. An isotope-dilution LC-MS/MS method for the simultaneous quantification of meropenem and its open-ring metabolite in serum. J Pharm Biomed Anal. 2021;197:113944.
Parker SL, Pandey S, Sime FB, et al. A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane-tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies. Clin Chem Lab Med. 2020;59:921–933.
Feliu C, Konecki C, Candau T, et al. Quantification of 15 antibiotics widely used in the critical care unit with a LC-MS/MS system: an easy method to perform a daily therapeutic drug monitoring. Pharmaceuticals . 2021;14:1214.
Nalbant D, Reeder JA, Li P, et al. Development and validation of a simple and sensitive LC-MS/MS method for quantification of ampicillin and sulbactam in human plasma and its application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2021;196:113899.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry, Bioanalytical Method Validation, 2018. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm070107.Pdf . Accessed February 28, 2022.
Fattouh R, Tijet N, McGeer A, et al. What is the appropriate meropenem MIC for screening of carbapenemase-producing Enterobacteriaceae in low-prevalence settings? Antimicrob Agents Chemother. 2015;60:1556–1559.